Search results
Developing Clinically Relevant Patient Management in Atopic Dermatitis
Medscape· 3 days agoA look at scientific findings in atopic dermatitis and how they are being transformed into clinical...
Chart Review Highlights Unique AD Features in Older Patients
Medscape· 5 days agoMore research is "needed to elucidate the unique features of elderly AD in pathophysiology and...
Fit for a dog? The latest science on CBD for pets
Popular Science via Yahoo News· 8 hours agoThis article was originally featured on Knowable Magazine. 13-year-old Norwich terrier, previously limping and stiff, able to enjoy walks again. A toy...
Stress can be "the triggering factor" for skin problems. Dermatologists share their advice.
CBS News· 3 days agoThere are many ways mental health can impact our physical health — but did you know stress can even...
Studies Show Linked Biological Pathways Driving Skin Inflammation
NBC 17 Raleigh· 4 days agoA certain biological pathway, a set of linked reactions in the body, drives the inflammation seen in the skin disease psoriasis, a new study finds. The work could lead to improved therapies ...
Got Tiny Blood Vessels on Your Face? Here's Why, and How To Treat Them
Well and Good· 3 days agoMore often than not, those red, spider-like clusters are just...broken blood vessels. Broken blood...
9 Analysts Have This To Say About Incyte - Incyte (NASDAQ:INCY)
Benzinga· 1 day agoIncyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma ...
Amalgamated Bank Decreases Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR)
ETF DAILY NEWS· 15 hours agoAmalgamated Bank decreased its stake in Kymera Therapeutics, Inc. (NASDAQ:KYMR – Free Report) by 6.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities and ...
Vanguard Personalized Indexing Management LLC Raises Position in Incyte Co. (NASDAQ:INCY)
ETF DAILY NEWS· 5 days agoVanguard Personalized Indexing Management LLC boosted its stake in Incyte Co. (NASDAQ:INCY – Free Report) by 30.4% during the fourth quarter, according to its most recent 13F filing with the ...
Dupixent® (dupilumab) Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS...
Benzinga· 4 days agoNOTUS results confirm landmark data from the Phase 3 BOREAS trial and show Dupixent significantly reduced exacerbations by 34% and improved lung function, compared to placebo, in uncontrolled chronic obstructive